Featured
BPC-157, KPV, and TB-500 Win Favorable PCAC Votes
BPC-157, KPV, and TB-500 won favorable PCAC votes, building momentum toward the 503A Bulks List and regulated peptide compounding.
Read the guideEditor’s picks
Featured articles
Featured
Rebody Journal
BPC-157, KPV, and TB-500 Win Favorable PCAC Votes
BPC-157, KPV, and TB-500 won favorable PCAC votes, building momentum toward the 503A Bulks List and regulated peptide compounding.
Read the guide
Featured
Rebody Journal
16 Million BPC-157 Doses and Seven Complaints: The PCAC Testimony
Dr. Alex Tatem brought data covering more than 16 million BPC-157 doses to PCAC—along with seven complaints and no clear attributable adverse safety signal.
Read the guide
Featured
Rebody Journal
Dr. Alex Tatem’s TB-500 PCAC Testimony: The Full Case
Human thymosin beta-4 trials, nearly 190,000 compounded vials, empty FDA adverse-event searches, and a favorable 8–6–1 PCAC vote.
Read the guide
Featured
Rebody Journal
What Is PCAC? Why the July 2026 Peptide Vote Matters
PCAC put seven peptides and the 503A Bulks List in the national spotlight. Here is what the committee does and why the July 2026 votes matter.
Read the guide
Featured
Rebody Journal
PCAC’s Peptide Votes Put the 503A Bulks List in Focus
BPC-157, KPV, and TB-500 put the 503A Bulks List in the spotlight—and built momentum for peptide compounding through licensed pharmacies.
Read the guide
Featured
Rebody Journal
PCAC Peptides: The Full July 2026 List, Schedule, and Results
The complete July 2026 PCAC peptide list, two-day schedule, favorable BPC-157, KPV and TB-500 results, and official webcast links.
Read the guide
Featured
Rebody Journal
KPV Wins a Favorable PCAC Vote for the 503A Bulks List
KPV won a favorable PCAC recommendation for the 503A Bulks List, joining BPC-157 and TB-500 in a major Day 1 for peptide compounding.
Read the guide
Featured
Rebody Journal
PCAC Live Stream July 24: DSIP, Epitalon, and Semax Votes
The July 24 PCAC livestream begins at 8 a.m. Eastern with emideltide (DSIP), Epitalon, and Semax on the peptide agenda.
Read the guide
Featured
Rebody Journal
Emideltide (DSIP) PCAC Vote: What to Watch on July 24
Emideltide—better known as DSIP—opens the July 24 PCAC peptide slate with separate free-base and acetate questions.
Read the guide
Featured
Rebody Journal
Epitalon PCAC Vote: The Longevity Peptide Heads to 503A Review
Epitalon brings sleep and longevity interest to PCAC Day 2 with separate free-base and acetate votes for the 503A Bulks List.
Read the guide
Featured
Rebody Journal
Semax PCAC Vote: Focus and Cognitive Peptide Takes Center Stage
Semax closes PCAC Day 2 with separate free-base and acetate votes and a spotlight on neurological and cognitive peptide interest.
Read the guide
Featured
Rebody Journal
PCAC Day 2 Preview: DSIP, Epitalon, and Semax
PCAC Day 2 moves from sleep to longevity to cognition with DSIP, Epitalon, and Semax following a major opening day.
Read the guide
Featured
Rebody Journal
What Favorable PCAC Votes Could Mean for DSIP, Epitalon, and Semax
Favorable PCAC votes would move DSIP, Epitalon, and Semax toward the 503A Bulks List and regulated peptide compounding.
Read the guide
Featured
Rebody Journal
Three Peptides to Watch at Tomorrow’s PCAC Meeting
DSIP brings sleep. Epitalon brings longevity. Semax brings cognition. All three reach PCAC tomorrow.
Read the guide